Burzynski: MULTICENTRIC GLIOMA (MCG)

� � � � � � � � � � � � � � � � �
# and % of Patients Resolving or Stabilizing Disease = Complete Response + Partial Response + Stable Disease
——————————————————————
14 / 100% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

11 / 100% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

11 / 91% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

10 / 91% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

7 / 64% – 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al

8 / 57% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide
======================================
# and % of Patients Showing Objective Response = Complete Response + Partial Response
——————————————————————
7 / 63.5% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

7 / 58% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

7 / 58% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

6 / 58% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

5 / 36% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide

30% – 1992 Antineoplastons – Protocol – ASTROCYTOMA

2 / 18% – 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al
======================================
# and % of Patients Showing Complete Response
——————————————————————
5 / 33% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

4 / 33% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

4 / 33% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

4 / 33% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

2 / 18% – # and % of Patients Showing Remission (definition of remission wasn’t provided): 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al

1 / 7% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide
======================================
# and % of Patients Showing Partial Response
——————————————————————
4 / 29% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide

4 / 25% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

3 / 25% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

3 / 25% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

2 / 25% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

2 / 18% – # and % of Patients Showing Remission (definition of remission wasn’t provided): 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al
======================================
# and % of Patients Showing Stable Disease
——————————————————————
5 / 46% – 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al

5 / 33% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

4 / 33% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

4 / 33% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

4 / 33% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

3 / 21% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide
======================================
# and % of Patients Showing Progressive Disease
——————————————————————
0 / 0% – Antineoplastons: MULTICENTRIC juvenile pilocytic ASTROCYTOMA

0 / 0% – 2004 Antineoplastons – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG)

0 / 0% – 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA

6 / 43% – Chamberlain and Grafe: 1995 – Protocol – solitary recurrent chiasmatic hypothalamic GLIOMAS treated with oral etoposide

4 / 36% – # and % of Patients Died: 7/1994 (1986 – 1992) – Protocol – MULTICENTRIC GLIOMA: Mamelak et al: 3 – from disease progression / 1 – from chemotherapy-induced toxicity
======================================
# and % of Patients Nonevaluable
——————————————————————
1 / 9% – non-evaluable due to only 4 weeks of ANP and lack of follow-up scans and died while on treatment due to a non-hemorrhaging brain infarction and was considered a treatment failure

1 / 9% – due to only 4 weeks of treatment / lack of follow-up scans. Patient died while on treatment due to brain infarct / counted as treatment failure 10/2003 Antineoplastons Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Alive and Well from 2 to >14 years Post-Diagnosis:
——————————————————————
10 – 2004 Antineoplastons: children with recurrent and progressive MULTICENTRIC GLIOMA (Pgs. 315-317 and 320-321)
======================================
Alive and Well from 2 to >14 years Post-Diagnosis:
——————————————————————
10 / 100% – 10/2003 Antineoplastons: Protocol – MULTICENTRIC GLIOMA
======================================
# and % of Patients Alive and Well (2 to 13 years Post Diagnosis):
——————————————————————
10 / 100% – 10/2003 Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (10 – Evaluable Patients)
======================================
# and % of Patients Alive and Well (2 to 13 years Post Diagnosis):
——————————————————————
10 / 100% – 10/2003 Antineoplastons: Protocol – MULTICENTRIC GLIOMA
======================================
Median Survival Post Diagnosis:
——————————————————————
7 years approximately – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
Median Overall Survival Post Diagnosis from initiation of Antineoplastons (ANP) with studies still ongoing:
——————————————————————
5 years – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
Median Progression-Free Survival (PFS):
——————————————————————
5 years – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
# and % of Patients Showing Progressive Disease:
——————————————————————
0 / 0% – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
� � � � � � � � � � � � � � � � �
Burzynski: Progression-Free Survival:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
� � � � � � � � � � � � � � � � �

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s